AbbVie IncNYSE:ABBV
- LAST PRICE178.7000
- TODAY'S CHANGE (%)1.7500 (0.9890%)
- Bid / Lots178.6800/ 15
- Ask / Lots178.7200/ 5
- Open / Previous Close177.0200 / 176.9500
- Day Range
- 52 Week Range
- Volume1,161,705
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ABBV |
|---|---|---|
| 09:32 ET | 137868 | 177.99 |
| 09:33 ET | 29693 | 177.84 |
| 09:35 ET | 33501 | 178.42 |
| 09:37 ET | 23869 | 178.025 |
| 09:39 ET | 22880 | 178 |
| 09:42 ET | 64421 | 178.5 |
| 09:44 ET | 33424 | 178.22 |
| 09:46 ET | 16606 | 178.3043 |
| 09:48 ET | 20895 | 178.185 |
| 09:50 ET | 19067 | 178.12 |
| 09:51 ET | 18467 | 178.25 |
| 09:53 ET | 41813 | 178.47 |
| 09:55 ET | 16802 | 178.4 |
| 09:57 ET | 39909 | 178.41 |
| 10:00 ET | 35803 | 178.46 |
| 10:02 ET | 52985 | 178.66 |
| 10:04 ET | 61352 | 178.85 |
| 10:06 ET | 87531 | 178.97 |
| 10:08 ET | 36971 | 178.655 |
| 10:09 ET | 37432 | 178.7 |
Today
AbbVie to Present at Citi's 2024 Global Healthcare Conference, from 2 hours ago by Dow Jones
2 hours ago by Dow Jones
Nov 22, 2024
DJ AbbVie Raised to Outperform From Market Perform by Leerink Partners, from 7:55AM ET on Friday Nov 22, 2024 by Dow Jones
7:55AM ET on Friday Nov 22, 2024 by Dow Jones
Nov 18, 2024
Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products, from 9:00AM ET on Monday Nov 18, 2024 by Dow Jones
9:00AM ET on Monday Nov 18, 2024 by Dow JonesDJ AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer, from 6:24AM ET on Monday Nov 18, 2024 by Dow Jones
6:24AM ET on Monday Nov 18, 2024 by Dow JonesAbbVie Receives European Commission Approval of ELAHERE(R) (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer, from 1:00AM ET on Monday Nov 18, 2024 by Dow Jones
1:00AM ET on Monday Nov 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
AbbVie Inc | 312.7B | 62.3x | -6.05% |
Merck & Co Inc | 250.9B | 21.1x | -43.23% |
Novartis AG | 231.4B | 18.2x | -5.59% |
Roche Holding AG | 233.7B | 19.3x | +3.28% |
AstraZeneca PLC | 204.4B | 31.9x | +17.52% |
Pfizer Inc | 145.4B | 35.0x | -7.10% |
Company Information
AbbVie Inc. is a diversified research-based biopharmaceutical company engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. It offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). It also offers CEL383 for the treatment of inflammatory bowel disease.
Contact Information
- Headquarters
- 1 N Waukegan RdNORTH CHICAGO, IL, United States 60064
- Phone
- 847-932-7900
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- Richard Gonzalez
- Chief Executive Officer, Director
- Robert Michael
- Chief Financial Officer, Executive Vice President
- Scott Reents
- Chief Human Resource Officer, Executive Vice President
- Timothy Richmond
- Executive Vice President - Research & Development, Chief Scientific Officer
- Roopal Thakkar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $312.7B |
|---|---|
Revenue (TTM) | $55.5B |
Shares Outstanding | 1.8B |
Dividend Yield | 3.67% |
Annual Dividend Rate | 6.5600 USD |
Ex-Dividend Date | 01-15-25 |
Pay Date | 02-14-25 |
Beta | 0.57 |
EPS | $2.87 |
Book Value | $5.87 |
P/E Ratio | 62.3x |
Price/Sales (TTM) | 5.6 |
Price/Cash Flow (TTM) | 23.1x |
Operating Margin | 24.89% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
